Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Gerritsen

Showing results (211-220 of 224) with videos related to

Pageof 23
Sort By:
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Cancer Immunology, Immunotherapy : CII|January 26, 2020
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trialSteve Boudewijns, Martine Bloemendal, Nienke de Haas, et al.
Clinical Genitourinary Cancer|December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Trials|November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
Ophthalmology|August 2, 2016
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal MelanomaKalijn F Bol, Thomas van den Bosch, Gerty Schreibelt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot StudyBastiaan M Privé, Steffie M B Peters, Constantijn H J Muselaers, et al.
European Urology Oncology|October 12, 2019
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer RegistryMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Clinical Genitourinary Cancer|August 24, 2019
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the NetherlandsHans M Westgeest, Malou C P Kuppen, Alphonsus J M van den Eertwegh, et al.
Journal of Palliative Medicine|August 20, 2021
High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-RegistryHans M Westgeest, Malou C P Kuppen, Fons A J M van den Eertwegh, et al.
European Urology Focus|July 30, 2017
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer RegistryHans M Westgeest, Carin A Uyl-de Groot, Reindert J A van Moorselaar, et al.
Pageof 23

Showing results (211-220 of 224) with videos related to

Sort By:
Pageof 23
The Lancet. Oncology|May 17, 2014
Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trialEugene D Kwon, Charles G Drake, Howard I Scher, et al.
Cancer Immunology, Immunotherapy : CII|January 26, 2020
Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trialSteve Boudewijns, Martine Bloemendal, Nienke de Haas, et al.
Clinical Genitourinary Cancer|December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Trials|November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
Ophthalmology|August 2, 2016
Adjuvant Dendritic Cell Vaccination in High-Risk Uveal MelanomaKalijn F Bol, Thomas van den Bosch, Gerty Schreibelt, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2021
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot StudyBastiaan M Privé, Steffie M B Peters, Constantijn H J Muselaers, et al.
European Urology Oncology|October 12, 2019
Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer RegistryMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Clinical Genitourinary Cancer|August 24, 2019
Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the NetherlandsHans M Westgeest, Malou C P Kuppen, Alphonsus J M van den Eertwegh, et al.
Journal of Palliative Medicine|August 20, 2021
High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-RegistryHans M Westgeest, Malou C P Kuppen, Fons A J M van den Eertwegh, et al.
European Urology Focus|July 30, 2017
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer RegistryHans M Westgeest, Carin A Uyl-de Groot, Reindert J A van Moorselaar, et al.
Pageof 23